symptoms arthritis
filed in Uncategorized on Aug.28, 2011
APA
Novartis Pharmaceuticals Corporation (2011, September 17). Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis. Medical News Today. Retrieved September 17, 2011 from http://www.medicalnewstoday.com/releases/234558.php
MLA
Novartis Pharmaceuticals Corporation. "Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis". Medical News Today, September 17, 2011. Web. 17 Sep, 2011.
Please note: If no author information is provided, the source is cited instead.
A drug used today to treat rheumatoid arthritis might be effective in treating asthma symptoms after two genetic variants have been found to increase asthma susceptibility, researchers from the Queensland Institute of Medical Research, Brisbane, Australia and others from around the world reported in The Lancet. The scientists found that cytokines - genes associated with signalling molecules that are involved in how the immune system functions - are involved in the development of asthma.
The authors explained that the causes of asthma have for long been poorly understood, in spite of several attempts to locate the genetic variants. Some recent GWAS (genome-wide associated studies) have only managed to locate some candidate genes which appear to have a slight effect on asthma risk. They have not fully explained the heritability of asthma, which leads doctors and scientists to believe that many genetic variations are involved.
Manuel Ferreira and an international team of experts set out to determine what genetic variations might be responsible for higher asthma risk by carefully examining all current GWAS and expanding on them.
They compared the genomes of thousands of asthma patients with individuals who do not have asthma across several populations and identified two genetic mutations that were strongly linked to asthma risk.
The genetic variants were:
- rs4129267 in the interleukin-6 receptor (IL6R) gene, and
- rs7130588 on chromosome 11q13.5
The drug tocilizumab is an example of a medication that blocks the receptor. It is already approved for rheumatoid arthritis treatment.
A high proportion of atopic (allergic) asthma patients were found to have the rs7130588 variant on chromosome 11q13.5. Interestingly, it was correlated with a nearby variant which has been recently associated with atopic dermatitis risk.
The authors believe that a gene in this region is involved in the development of allergic sensitisation, which raises allergic asthma risk.
The authors wrote:
"At this stage it is unclear which gene underlies the association with 11q13.5. Given that no specific gene in this region has been directly implicated in allergic disease previou. sly, further characterisation of this region of association is likely to discover novel molecular mechanisms involved in the causality of eczema, atopy, and asthma."
So far, no single genetic cause has been located which is responsible for over 1% of asthma heritability, the authors added. Their findings demonstrate that asthma is a complex condition, and most likely several genes of small effect combine and interact with environmental risk factors in driving asthma risk.
The scientists concluded:
"Our results are consistent with the contribution of hundreds or potentially thousands of variants with weak effects on asthma risk, which can be identified through larger GWAS as already shown with other diseases."
Kathleen Barnes, from Johns Hopkins University, Baltimore, USA, in a Comment in the same journal wrote:
"Success in the validation of various candidates (and their pathways) that are already on the asthma shortlist of potential causal genes, and the biological insight to be gained from the novel findings in this report are grounds for optimism in the continuation of the GWAS approach. Combination of GWAS with next-generation technologies will undoubtedly further help to disentangle the molecular underpinnings of complex traits such as asthma."
Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
- Additional
- References
- Citations
ymptoms arthritis smptoms arthritis syptoms arthritis symtoms arthritis sympoms arthritis symptms arthritis symptos arthritis symptom arthritis symptoms rthritis symptoms athritis symptoms arhritis symptoms artritis symptoms arthitis symptoms arthrtis symptoms arthriis symptoms arthrits symptoms arthriti aymptoms arthritis dymptoms arthritis stmptoms arthritis sumptoms arthritis synptoms arthritis symotoms arthritis symproms arthritis sympyoms arthritis symptims arthritis symptpms arthritis symptons arthritis symptoma arthritis symptomd arthritis symptoms srthritis symptoms aethritis symptoms atthritis symptoms arrhritis symptoms aryhritis symptoms artgritis symptoms artjritis symptoms artheitis symptoms arthtitis symptoms arthrutis symptoms arthrotis symptoms arthriris symptoms arthriyis symptoms arthritus symptoms arthritos symptoms arthritia symptoms arthritid
ysmptoms arthritis smyptoms arthritis sypmtoms arthritis symtpoms arthritis sympotms arthritis symptmos arthritis symptosm arthritis symptom sarthritis symptoms rathritis symptoms atrhritis symptoms arhtritis symptoms artrhitis symptoms arthirtis symptoms arthrtiis symptoms arthriits symptoms arthritsi symptoms arthriti ssymptoms arthritis syymptoms arthritis symmptoms arthritis sympptoms arthritis sympttoms arthritis symptooms arthritis symptomms arthritis symptomss arthritis symptoms aarthritis symptoms arrthritis symptoms artthritis symptoms arthhritis symptoms arthrritis symptoms arthriitis symptoms arthrittis symptoms arthritiis symptoms arthritiss
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Novartis Pharmaceuticals Corporation (2011, September 17). Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis. Medical News Today. Retrieved September 17, 2011 from http://www.medicalnewstoday.com/releases/234558.php
MLA
Novartis Pharmaceuticals Corporation. "Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis". Medical News Today, September 17, 2011. Web. 17 Sep, 2011.
Please note: If no author information is provided, the source is cited instead.
A drug used today to treat rheumatoid arthritis might be effective in treating asthma symptoms after two genetic variants have been found to increase asthma susceptibility, researchers from the Queensland Institute of Medical Research, Brisbane, Australia and others from around the world reported in The Lancet. The scientists found that cytokines - genes associated with signalling molecules that are involved in how the immune system functions - are involved in the development of asthma.
The authors explained that the causes of asthma have for long been poorly understood, in spite of several attempts to locate the genetic variants. Some recent GWAS (genome-wide associated studies) have only managed to locate some candidate genes which appear to have a slight effect on asthma risk. They have not fully explained the heritability of asthma, which leads doctors and scientists to believe that many genetic variations are involved.
Manuel Ferreira and an international team of experts set out to determine what genetic variations might be responsible for higher asthma risk by carefully examining all current GWAS and expanding on them.
They compared the genomes of thousands of asthma patients with individuals who do not have asthma across several populations and identified two genetic mutations that were strongly linked to asthma risk.
The genetic variants were:
- rs4129267 in the interleukin-6 receptor (IL6R) gene, and
- rs7130588 on chromosome 11q13.5
The drug tocilizumab is an example of a medication that blocks the receptor. It is already approved for rheumatoid arthritis treatment.
A high proportion of atopic (allergic) asthma patients were found to have the rs7130588 variant on chromosome 11q13.5. Interestingly, it was correlated with a nearby variant which has been recently associated with atopic dermatitis risk.
The authors believe that a gene in this region is involved in the development of allergic sensitisation, which raises allergic asthma risk.
The authors wrote:
"At this stage it is unclear which gene underlies the association with 11q13.5. Given that no specific gene in this region has been directly implicated in allergic disease previou. sly, further characterisation of this region of association is likely to discover novel molecular mechanisms involved in the causality of eczema, atopy, and asthma."
So far, no single genetic cause has been located which is responsible for over 1% of asthma heritability, the authors added. Their findings demonstrate that asthma is a complex condition, and most likely several genes of small effect combine and interact with environmental risk factors in driving asthma risk.
The scientists concluded:
"Our results are consistent with the contribution of hundreds or potentially thousands of variants with weak effects on asthma risk, which can be identified through larger GWAS as already shown with other diseases."
Kathleen Barnes, from Johns Hopkins University, Baltimore, USA, in a Comment in the same journal wrote:
"Success in the validation of various candidates (and their pathways) that are already on the asthma shortlist of potential causal genes, and the biological insight to be gained from the novel findings in this report are grounds for optimism in the continuation of the GWAS approach. Combination of GWAS with next-generation technologies will undoubtedly further help to disentangle the molecular underpinnings of complex traits such as asthma."
Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
- Additional
- References
- Citations